Raymond James & Associates’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Raymond James & Associates’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-38,788	Closed	-$926K	–	3810
2019 Q4	$926K	Sell	38,788 -4,795	-11%	-$132K	﹤0.01%	2311
2019 Q3	$1.17M	Sell	43,583 -6,308	-13%	-$177K	﹤0.01%	2104
2019 Q2	$1.35M	Sell	49,891 -26,383	-35%	-$827K	﹤0.01%	2035
2019 Q1	$2.65M	Buy	76,274 +41,610	+120%	+$1.2M	﹤0.01%	1582
2018 Q4	$677K	Sell	34,664 -18,653	-35%	-$384K	﹤0.01%	2330
2018 Q3	$1.42M	Buy	53,317 +13,015	+32%	+$425K	﹤0.01%	2024
2018 Q2	$1.52M	Buy	40,302 +20,441	+103%	+$782K	﹤0.01%	1942
2018 Q1	$649K	Buy	19,861 +11,961	+151%	+$525K	﹤0.01%	2406
2017 Q4	$385K	Buy	7,900 +3,330	+73%	+$168K	﹤0.01%	2699
2017 Q3	$247K	Buy	+4,570	New	+$268K	﹤0.01%	2910
2016 Q4	–	Sell	-10,758	Closed	-$244K	–	3406
2016 Q3	$244K	Buy	10,758 +1,168	+12%	+$27.4K	﹤0.01%	2751
2016 Q2	$226K	Buy	+9,590	New	+$237K	﹤0.01%	2579
2016 Q1	–	Sell	-19,947	Closed	-$1.03M	–	2986
2015 Q4	$1.03M	Buy	+19,947	New	+$967K	﹤0.01%	1624

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Raymond James & Associates's PTLA Position: Q1 2020 in Review

Raymond James & Associates sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 38,788 shares — an estimated $926K sold.

Raymond James & Associates first reported a position in PTLA in Q4 2015 and held it in 13 quarters. The position peaked at $2.65M in Q1 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Raymond James & Associates reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Raymond James & Associates sold 38,788 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $926K.
Raymond James & Associates first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 13 quarters.
Raymond James & Associates's Portola Pharmaceuticals, Inc. position peaked at $2.65M in Q1 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.